Serina enrolls first patient in Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease.

Serina Therapeutics, Inc., a clinical-stage biotechnology company developing drug candidates using its proprietary POZ Platform™ drug optimization technology, announced the enrollment of the first patient in its Phase 1b registrational trial evaluating SER-252 for advanced Parkinson’s disease. The Phase 1b study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson’s disease whose symptoms are not adequately managed by existing standard-of-care treatments. Serina remains on track to begin dosing during the current quarter, consistent with prior guidance.

Steve Ledger, Chief Executive Officer of Serina Therapeutics, said that enrolling the first patient marks an important operational milestone in advancing SER-252 into the clinic. He noted that the company has established a strong operational presence in Australia and is working closely with leading Parkinson’s disease specialists and patient advocacy organizations to ensure efficient patient enrollment. 

Dr. Ledger emphasized that, with FDA alignment on a registrational development strategy under a 505(b)(2) NDA pathway, the company is focused on executing the trial and generating meaningful clinical data for patients with advanced Parkinson’s disease, a population with significant unmet medical needs. Serina has partnered with Parkinson’s Australia and Neuroscience Trials Australia to support patient identification and enrollment. The company plans to provide additional updates on the trial as patient enrollment progresses.